California voters approved Proposition 38, a $8.4 billion state bond for immunology and immunotherapy research, in the November 3, 2026 election. The Associated Press called the measure on Monday, November 9, 2026, with about 54% of votes counted in favour, according to CalMatters and the Daily Bruin. Half of the money is directed to a single UC-affiliated research institute and half to selected public universities and nonprofits.
What happened and when
The Associated Press called Proposition 38 for the yes side on the evening of Monday, November 9, 2026, six days after election day. CalMatters reported the result as 54% to 46% per the AP, and the Daily Bruin reported 54.2% yes at that point in the count. Both figures are from the count on election night plus six days, so the final certified margin may differ as remaining ballots are counted.
What the measure authorizes
According to CalMatters, the bond is for immunology and immunotherapy research aimed at diseases such as cancer, heart disease and Alzheimer’s. The money divides into two halves:
- An institute half. Half goes to one research institute affiliated with the University of California. CalMatters reported that the only organization meeting the measure’s criteria is the California Institute for Immunology and Immunotherapy, a founding member of the UCLA Research Park.
- A competitive half. The other half goes to selected public universities and nonprofit research institutions in California through a competitive grant process.
The Daily Bruin reported that an Advisory and Accountability Research Council would set research goals and grant criteria, with seven UC representatives and 10 to 15 members from other universities and nonprofit research institutes. Drugs developed directly through the funding must be discounted at least 20% for Californians, and 10% of their revenue goes to the state general fund, according to the same report.
Cost to the state
The state’s fiscal estimate, as quoted in CalMatters’ voter guide, is an increased state cost of $500 million to $600 million a year for about 20 years to repay the bonds, partly or fully offset if the funded research generates revenue. CalMatters put the total at roughly $12 billion with interest.
The criticism
Opposition came from several directions, as CalMatters reported. Robert Kaplan, a Stanford senior scholar, the No on 38 campaign and the League of Women Voters opposed the measure, as did the editorial boards of several major California newspapers. Their main arguments were that it funds only one subset of biomedical research, that commercial returns are uncertain, and that one nonprofit would receive half the money.
CalMatters also reported that the institute’s primary funder, Gary K. Michelson, wrote the measure and was its largest political donor, and that the institute has a 2024 affiliation agreement with UCLA giving the university 7.5% of net revenue from products that reach market. Supporters, including Gov. Gavin Newsom and the California Democratic Party, argued that a California fund is needed as federal science funding is reduced, and that the bond would pay for itself through revenue sharing, per CalMatters.
What it means for researchers and research offices
This is editorial interpretation, not reported fact. The competitive half is limited to a defined group of public and nonprofit institutions, so eligibility will depend on the measure’s text and on criteria the advisory council sets. Research offices at California institutions will want to watch for how the council is constituted, what grant criteria it publishes, and how intellectual property and revenue-sharing terms are written into awards. The 20% discount and 10% revenue provisions make licensing structure a central issue, so technology licensing offices and the terms of any license agreement arising from funded work are likely to matter. Because the competitive pool resembles a discretionary grant programme, applicants should expect competitive, criteria-driven selection once rules are issued.
What to watch next
- Certification of the final vote count.
- Appointment of the advisory and accountability council and publication of grant criteria.
- The timing of bond sales and the first awards, which have not been announced.
See also the CASRAI technology transfer coverage for background on licensing offices.
